Recent Finacing
Recent Raise
Trefoil Therapeutics develops engineered FGF‑1 proteins (eFGF‑1), including lead candidate TTHX1114, to stimulate corneal endothelial and epithelial cell proliferation and migration via intravitreal and topical clinical programs.
